SYNGR2 as a Multifaceted Biomarker in Hepatocellular Carcinoma Linking Prognosis, Immune Microenvironment and Therapeutic Response
SYNGR2 has emerged as a multifaceted biomarker candidate in HCC, associated with prognosis, an immunosuppressive microenvironment, and differential therapeutic responses, and its integration into clinical models could enhance prognostic stratification and guide personalized treatment strategies.